VEGF Trap-Eye 2.0mg
VGFT-OD-0819
Phase 3 mab completed
Quick answer
VEGF Trap-Eye 2.0mg for Macular Edema Secondary to Central Retinal Vein Occlusion is a Phase 3 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Phase
- Phase 3
- Modality
- mab
- Status
- completed